Literature DB >> 8546719

The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium.

M F Liu1, H Kohsaka, H Sakurai, M Azuma, K Okumura, I Saito, N Miyasaka.   

Abstract

OBJECTIVE: To investigate the expressions of co-stimulatory molecules CD86 (B7-2, B70) and CD28 by cells obtained from the synovial tissues (ST) and synovial fluids (SF) of patients with rheumatoid arthritis (RA).
METHODS: Monoclonal antibodies (MAb) against CD86 and CD28 were used for immunochemical study of synovia from 18 RA patients, 4 osteoarthritis (OA) patients, and 4 normal subjects. These MAb were also used for flow cytometry of isolated ST cells from 8 RA and 5 OA patients and of SF mononuclear cells from 5 RA and 5 OA patients.
RESULTS: Immunohistochemical examination revealed that CD86+ cells occurred in 11 of the 18 RA synovia, but in none of the 4 OA or 4 normal synovia. Most of the positive cells had macrophage-like morphology, and surrounded lymphoid aggregates. Most cells within lymphoid aggregates were stained positively for CD28. Flow cytometry showed that CD86+ cells comprised 2.9-33.4% (average 14.3%) of the total ST cells and 2.1-14.9% (average 6.1%) of the total SF mononuclear cells from RA patients. Approximately 40% of the CD86+ cells expressed CD14. A majority (mean 72%, range 57-89%) of the T cells in ST and SF expressed CD28. RA synovia expressed more CD86 molecules than did OA synovia (mean frequency of positive cells 14.3% versus 2.8%; mean fluorescence intensity 104.6 versus 40.9).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8546719     DOI: 10.1002/art.1780390115

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis.

Authors:  A Kawakami; K Eguchi; N Matsuoka; M Tsuboi; S Urayama; Y Kawabe; T Aoyagi; K Maeda; S Nagataki
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 2.  Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution.

Authors:  Annabel Kuek; Brian L Hazleman; Andrew J K Ostör
Journal:  Postgrad Med J       Date:  2007-04       Impact factor: 2.401

3.  Reduced serum B7-H3 levels in patients with ankylosing spondylitis.

Authors:  Ruhong Yan; Yae Hu; Peijuan Yu; Huiyan Wen; Ping Feng; Shun Yang
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

4.  Glandular and extraglandular expression of costimulatory molecules in patients with Sjögren's syndrome.

Authors:  R Matsumura; K Umemiya; T Goto; T Nakazawa; M Kagami; H Tomioka; E Tanabe; T Sugiyama; M Sueishi
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

5.  Costimulatory blockade: A novel approach to the treatment of glomerular disease?

Authors:  Pasquale Esposito; Teresa Rampino; Antonio Dal Canton
Journal:  World J Methodol       Date:  2015-06-26

6.  Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes.

Authors:  N Lambert; P L Lescoulié; B Yassine-Diab; G Enault; B Mazières; C De Préval; A Cantagrel
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

Review 7.  Cell-cell interactions in synovitis: antigen presenting cells and T cell interaction in rheumatoid arthritis.

Authors:  T Aarvak; J B Natvig
Journal:  Arthritis Res       Date:  2000-10-27

8.  Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis.

Authors:  Jiro Yamana; Masahiro Yamamura; Akira Okamoto; Tetsushi Aita; Mitsuhiro Iwahashi; Katsue Sunahori; Hirofumi Makino
Journal:  Arthritis Res Ther       Date:  2004-10-13       Impact factor: 5.156

9.  Synovial Macrophages: Past Life, Current Situation, and Application in Inflammatory Arthritis.

Authors:  Lin-Kun Bai; Ya-Zhen Su; Xue-Xue Wang; Bing Bai; Cheng-Qiang Zhang; Li-Yun Zhang; Gai-Lian Zhang
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

10.  Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity.

Authors:  Eric Toussirot; Philippe Saas; Marina Deschamps; Fabienne Pouthier; Lucille Perrot; Sylvain Perruche; Jacqueline Chabod; Pierre Tiberghien; Daniel Wendling
Journal:  Arthritis Res Ther       Date:  2009-07-01       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.